DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy remains the primary treatment option, yet TNBC frequently develops resista...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wen-yu Cai, Xin-xian Cai, Yi-ran Fei, Rui Ye, Ding-ming Song, Dan Hu, Wan-wan Zhang, Ming-fei Xia, Xiao-xiao Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Oncology
Subjects:	triple-negative breast cancer DNA methylation inhibitors immune checkpoint inhibitors immune evasion epigenetic therapy personalized medicine
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1534055/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Overcoming immune evasion with innovative multi-target approaches for glioblastoma
by: Hai Su, et al.
Published: (2025-01-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01)

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
by: Xinyu Ren, et al.
Published: (2025-04-01)

Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population
by: Wang RH, et al.
Published: (2025-02-01)

Construction of the bromodomain-containing protein-associated prognostic model in triple-negative breast cancer
by: Wei Chen, et al.
Published: (2025-01-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Autoimmune pancerebellitis as an immune-related adverse event: an illustrative case
by: D. Valančius, et al.
Published: (2021-12-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation
by: Xinjun Lu, et al.
Published: (2024-11-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors
by: Daniel Cathalifaud, et al.
Published: (2025-01-01)

David Slays Goliath: Exceptional Efficacy of Oral Vinorelbine in Conquering Metastatic Finger Angiosarcoma
by: Te-Lin Hsu, et al.
Published: (2024-01-01)

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies
by: Li-Chun Lu, et al.
Published: (2023-04-01)

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database
by: Alexandre O. Gérard, et al.
Published: (2025-01-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
by: Takafumi Yanagisawa, et al.
Published: (2025-02-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy
by: Cheng-Wei Huang, et al.
Published: (2024-01-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)